Table 2 Correlation analyses of recipients of bone marrow transplantation.
From: Nationwide study of COVID-19 outcomes in hematologic patients following bone marrow transplantation
Characteristic | Mortality | |||
|---|---|---|---|---|
Total, N = 2,3241 | No, N = 2,0221 | Yes, N = 3021 | p value2 | |
Year | < 0.001 | |||
2020 | 597 (26%) | 516 (26%) | 81 (27%) | |
2021 | 521 (22%) | 418 (21%) | 103 (34%) | |
2022 | 1,206 (52%) | 1,088 (54%) | 118 (39%) | |
Age | 58 (45, 66) | 58 (45, 65) | 61 (50, 67) | 0.004 |
Sex (men) | 1,438 (62%) | 1,249 (62%) | 189 (63%) | 0.79 |
ICU admissions | 349 (15%) | 191 (9.4%) | 158 (52%) | < 0.001 |
ICU LOS | 10 (3, 23) | 7 (2, 18) | 15 (6, 26) | < 0.001 |
Hospitalization LOS | 9 (5, 22) | 8 (4, 20) | 23 (9, 43) | < 0.001 |
Comorbidities | ||||
Type 2 diabetes | 276 (12%) | 244 (12%) | 32 (11%) | 0.46 |
Coronary disease | 72 (3.1%) | 63 (3.1%) | 9 (3.0%) | 0.90 |
Heart failure | 109 (4.7%) | 80 (4.0%) | 29 (9.6%) | < 0.001 |
Hypertension | 543 (23%) | 467 (23%) | 76 (25%) | 0.43 |
Cerebrovascular disease | 4 (0.2%) | 2 (< 0.1%) | 2 (0.7%) | 0.084 |
Obesity | 99 (4.3%) | 91 (4.5%) | 8 (2.6%) | 0.14 |
Dementia | 8 (0.3%) | 4 (0.2%) | 4 (1.3%) | 0.013 |
Chronic kidney disease | 186 (8.0%) | 159 (7.9%) | 27 (8.9%) | 0.52 |
Chronic liver disease | 11 (0.5%) | 10 (0.5%) | 1 (0.3%) | > 0.99 |
Chronic pulmonary disease | 180 (7.7%) | 160 (7.9%) | 20 (6.6%) | 0.43 |
Solid tumor | 104 (4.5%) | 78 (3.9%) | 26 (8.6%) | < 0.001 |
Hematologic malignancies | ||||
Hodgkin lymphoma | 66 (2.8%) | 59 (2.9%) | 7 (2.3%) | 0.56 |
Non-Hodgkin lymphoma | 417 (18%) | 362 (18%) | 55 (18%) | 0.90 |
Multiple myeloma and malignant plasma cell neoplasms | 513 (22%) | 459 (23%) | 54 (18%) | 0.060 |
Acute leukemia | 620 (27%) | 520 (26%) | 100 (33%) | 0.007 |
Chronic myeloproliferative disorders | 66 (2.8%) | 51 (2.5%) | 15 (5.0%) | 0.017 |
